Hypoxia in cancer: significance and impact on clinical outcome
By P. Vaupel, A. Mayer. Cancer Metastasis Review, 2007
2,205 citations recorded by the source corpus.
Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/f817132fdda5ea410e37ecb0615b1ee7f8f1a0ea
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Jeremy N. Rich
- R. Hill
- J. Lathia
- Michael Baumann
- Mechthild Krause
- Anita B. Hjelmeland
- C. Roma-Rodrigues
- Alexandra R. Fernandes
In Cardiology and Cardiovascular Medicine
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Studies have shown that 50–60% of solid tumors are hypoxic, which disrupts the expression of multiple tumor genes profiles and causes tumor necrosis, stimulating the spread and metastasis of tumor.(61) Since tumor growth and reproduction require substantial energy, the tumor cells in a hypoxic envir”
- Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. (2016, background): “In early key findings, O2-sensitive microsensors were used to show that tumor hypoxia was associated with tumor progression (Vaupel & Mayer, 2007).”
- Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008, neutral): “Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth.”
- Hypoxia inducible mir-210 regulates normoxic gene expression involved in tumor initiation (2009, positive): “Therefore, overexpression of mir-210 could predict poor prognosis in these cases, maybe because mir-210 is a surrogate marker for tumor hypoxia, which is a well-known independent indicator of poor patient outcome (Vaupel and Mayer, 2007).”
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016, background): “HIF-1 is a major oncogenic factor [72] and inhibition of HIF-1 has been applied for the treatment of cancer[73-75].”
- Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. (2018, background): “Hypoxia is an important hallmark of solid tumors, and is associated with tumor angiogenesis, glycolysis, growth factor signaling, aggressive phenotypes, and poor prognosis (8, 29).”
- The role of hypoxia-inducible factors in tumorigenesis (2008, background): “solid tumors contain areas of hypoxic and/or anoxic tissues that develop as a result of an imbalance between oxygen supply and consumption in proliferating tumors.(45) Low oxygen”
- Hypoxic radiosensitization: adored and ignored. (2007, background): “The presence of measurable hypoxia is associated with poor outcome.(6,7,21) This is seen not only after treatment with radiotherapy, but also has been described as a phenomenon linked with a more aggressive tumor phenotype (eg, the presence of severe hypoxia in sarcomas is a prominent sign of poor p”
- Targeting Tumor Microenvironment for Cancer Therapy (2019, background): “In addition, the TME may experience two types of low oxygenation events, chronic and acute/cycling hypoxia [18,43].”
- Exploring the role of cancer stem cells in radioresistance (2008, background): “The vast majority of experimental and human tumours contain hypoxic cells, and levels of hypoxia show intertumoural as well as intratumoural heterogeneit”
- Hypoxic enhancement of exosome release by breast cancer cells (2012, background): “Hypoxia is an important feature of tumours, and is associated with aggressive tumour phenotypes and poor patient outcomes [17].”
- Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability (2008, neutral): “gov/cancertopics/types/head-and-neck">head and neck”
- Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements☆ (2017, background): “Tumor hypoxia, which bears clinical implications on treatment outcome, is one of the major challenges in the treatment of cancer [151, 152].”
- MR Vascular Fingerprinting: A New Approach to Compute Cerebral Blood Volume, Mean Vessel Radius, and Oxygenation Maps in the Human Brain (2013, background): “All these parameters contributing to BOLD are potentially important biomarkers for studying angiogenesis or hypoxic processes in pathologies such as cancer (Carmeliet and Jain, 2000; Vaupel and Mayer, 2007) or stroke (Sobesky et al.”
- Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells (2009, positive): “Hypoxia is a well-recognized tumor microenvironmental condition that is linked to poor patient outcome and resistance to therapies (Teicher, 1994; Liang, 1996; Semenza, 2004; Chi et al., 2006; Vaupel and Mayer, 2007; Sathornsumetee et al., 2008).”